Antidiabetic Effects on Intrahepatic Fat

NCT03068065 on ClinicalTrials.gov · last registry update 2017-03-01

Finished November 2014, after enrolling 87 people. Primary outcome, as filed: Intrahepatic fat. liraglutide is approved in the US, but not for mash nafld — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Sponsor type: Other
Enrollment: 87
Started: 2014-05
Primary completion: 2014-11 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Intrahepatic fat

Conditions studied

Non-Alcoholic Fatty Liver Disease · Type2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.